Dakota Wealth Management lifted its stake in Eli Lilly And Co (NYSE:LLY) by 375.3% in the 1st quarter, HoldingsChannel.com reports. The firm owned 36,965 shares of the company’s stock after purchasing an additional 29,188 shares during the quarter. Eli Lilly And Co accounts for approximately 1.0% of Dakota Wealth Management’s portfolio, making the stock its 26th biggest position. Dakota Wealth Management’s holdings in Eli Lilly And Co were worth $4,798,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Oregon Public Employees Retirement Fund raised its position in Eli Lilly And Co by 17,720.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock worth $367,000 after acquiring an additional 42,182,367 shares during the last quarter. Norges Bank acquired a new position in Eli Lilly And Co during the fourth quarter worth about $1,056,086,000. FMR LLC raised its position in Eli Lilly And Co by 83.9% during the fourth quarter. FMR LLC now owns 13,687,081 shares of the company’s stock worth $1,583,870,000 after acquiring an additional 6,242,865 shares during the last quarter. Amundi Pioneer Asset Management Inc. raised its position in Eli Lilly And Co by 165.4% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 6,012,822 shares of the company’s stock worth $695,804,000 after acquiring an additional 3,747,482 shares during the last quarter. Finally, BlackRock Inc. raised its position in Eli Lilly And Co by 3.0% during the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock worth $7,979,649,000 after acquiring an additional 2,030,845 shares during the last quarter. Hedge funds and other institutional investors own 79.17% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $122.48, for a total value of $25,108,400.00. Following the completion of the sale, the insider now directly owns 117,641,684 shares in the company, valued at $14,408,753,456.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Enrique A. Conterno sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $121.00, for a total transaction of $3,025,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 870,959 shares of company stock valued at $109,672,752. Company insiders own 0.11% of the company’s stock.
LLY has been the subject of a number of research reports. Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. UBS Group cut their target price on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research report on Friday, February 8th. Bank of America set a $129.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Citigroup set a $124.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Tuesday, February 26th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Eli Lilly And Co in a research report on Tuesday, March 12th. They set an “overweight” rating and a $140.00 target price for the company. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $118.83.
NYSE:LLY opened at $115.80 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.12 and a debt-to-equity ratio of 5.50. The company has a market capitalization of $112.86 billion, a PE ratio of 20.86, a PEG ratio of 2.07 and a beta of 0.27. Eli Lilly And Co has a 1-year low of $79.41 and a 1-year high of $132.13.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, beating analysts’ consensus estimates of $1.32 by $0.01. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.31 earnings per share. Research analysts anticipate that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Friday, May 17th will be given a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.23%. The ex-dividend date is Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Why is a lock-up period needed for an IPO?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).